Associations between CD160 polymorphisms and autoimmune thyroid disease: a case-control study

Abstract Background Recent researches suggest that the CD160/HVEM/LIGHT/BTLA signaling pathway may contribute to the pathogeneses of autoimmune diseases, but the relationship between CD160 polymorphisms and autoimmune thyroid disease (AITD) has not been reported yet. This study aimed to evaluate the associations between CD160 polymorphisms and AITD. Methods A total of 1017 patients with AITD (634 Graves’ disease and 383 Hashimoto’s thyroiditis) and 856 unrelated healthy controls were recruited into our study. Odds ratios (ORs) with 95% confidence interval (95%CI) were calculated through logistic regression analyses. The CD160 SNPs were detected using Hi-SNP high-throughput genotyping. Results There was a statistically significant difference between Graves’ disease patients and the control group with respect to both the genotype distribution (P = 0.014) and allele frequency of rs744877 (P = 0.034). A significant association of CD160 rs744877 with AITD was observed before adjusted age and gender under a dominant model (OR = 0.79, 95%CI 0.66–0.95; P = 0.013) and an additive model (OR = 0.77, 95%CI 0.64–0.94, P = 0.008), and was also observed after adjusted age and gender under a dominant model (OR = 0.78, 95%CI 0.65–0.95; P = 0.011) and an additive model (OR = 0.76, 95%CI 0.63–0.93, P = 0.007). A significant association of rs744877 with Graves’ disease was observed under an allele model (OR = 0.84, 95%CI 0.71–0.98, P = 0.027), a dominant model (OR = 0.74, 95%CI 0.60–0.91; P = 0.005), and an additive model (OR = 0.72, 95%CI 0.58–0.90, P = 0.004). Multivariate logistic regression analyses suggested that the association remained significant after adjustment for age and gender. However, rs744877 was not related to Hashimoto’s thyroiditis. Furthermore, CD160 rs3766526 was not significantly related to either Graves’ disease or Hashimoto’s thyroiditis. Conclusion This is the first identification of the association of CD160 rs744877 with Graves’ disease. Our findings add new data to the genetic contribution to Graves’ disease susceptibility and support the crucial role of the CD160/HVEM/LIGHT/BTLA pathway in the pathogenesis of Graves’ disease